Focus at Infinity Pharmaceuticals Inc., which had shifted in the wake of disappointing data from its Hedgehog inhibitor program in early 2012, narrowed further this week following a Phase II miss with heat-shock protein 90 (Hsp90) inhibitor retaspimycin hydrochloride in non-small-cell lung cancer (NSCLC).